Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oncolytics Collaborators to Present Preclinical Research in Multiple Myeloma and Melanoma

Published: Tuesday, April 08, 2014
Last Updated: Tuesday, April 08, 2014
Bookmark and Share
Research collaborators will make two poster presentations at the AACR 2014 Annual Meeting.

Oncolytics Biotech Inc. has announced that research collaborators will make two poster presentations at the American Association for Cancer Research 2014 Annual Meeting. The Meeting is being held from April 6th to 9th, 2014 in San Diego, CA.

"The data presented by these collaborators is contributing to our evolving understanding of how REOLYSIN® works, what biomarkers may be predictive of improved patient outcomes, and the potential synergies with other drugs in specific indications," said Dr. Brad Thompson, President and CEO of Oncolytics. "There is ongoing clinical work in both multiple myeloma and metastatic melanoma and these data will help shape future studies in these indications."

The first poster, titled "Reovirus synergy with proteosome inhibitor carfilzomib and Akt inhibitor perifosine overcomes therapy resistance of multiple myeloma: promising preclinical activity," is being presented by Thirukkumaran et al.

The poster presents findings demonstrating that reovirus acts synergistically with carfilzomib and/or perifosine in oncolysis of therapy resistant multiple myeloma cell lines. Synergistic cytotoxicity was observed with reovirus and carfilzomib and perifisone in both reovirus resistant OPM2, KMS-11 or sensitive RPMI8226 cell lines. Reovirus resistant cell lines demonstrated enhanced synergism in comparison to reovirus sensitive RPMI8226.

The second poster, titled "Molecular and immunological correlates of latent versus productive reoviral infection in cancers" is being presented by Mansfield et al. The poster presents findings following analysis of several human multiple myeloma cell lines either resistant or sensitive to reovirus infection and a metastatic melanoma model in mice after reoviral infection.

Myeloma cell lines resistant to reoviral infection showed that the majority of the cancer cells had latent reoviral infection with very weak productive infection (productive/latent reoviral infection 6%). Myeloma cells sensitive to reoviral infection showed many cells with a productive viral infection (productive/latent reoviral infection was 50%). P38 expression was identical in the resistant and sensitive myeloma cell lines; two molecular markers that marked the reoviral sensitive myeloma cell lines were high CUG2 expression and low ammonia production.

In the metastatic melanoma model, latent infection was dominant in mice treated with reovirus alone; productive infection was dominant in mice treated with reovirus and chemotherapy. In both the cell lines and metastatic melanoma model, productive infection was associated with elevated caspase-3 expression. In the metastatic melanoma model, productive infection was associated with increased T cell and natural killer cell infiltration of the tumor.

The posters will be available on the Oncolytics website at http://www.oncolyticsbiotech.com/for-investors/presentations.

A clinical study entitled "Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma" will examine the use of REOLSYIN® in combination with carfilzomib (ClinicalTrials.gov Identifier: NCT02101944) in patients with relapsed or refractory myeloma.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncolytics Announces First Patients Treated in Phase 1b Study
Study of pembrolizumab in combination with REOLYSIN® and chemotherapy in advanced pancreatic cancer patients.
Thursday, January 21, 2016
Oncolytics Collaborators Present Preclinical Research on Liver Cancer
Dr. Adel Jebar has presented a poster at the 8th Annual International Conference on Oncolytic Virus in UK.
Tuesday, April 15, 2014
Oncolytics Collaborators Present at UK Oncolytic Virus Conference
Collaborators present translational brain cancer clinical data and immunomodulatory preclinical research.
Tuesday, April 15, 2014
Oncolytics Biotech® Announces Third Quarter 2013 Results
Company announces its financial results and operational highlights.
Monday, November 11, 2013
Oncolytics Biotech® Announces Addition to Senior Management Team
Appointment of Dr. Jeremy Grushcow to the role of General Counsel.
Monday, September 16, 2013
Oncolytics Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN®
Final progression-free survival and safety data for the study will be reported later in 2013.
Tuesday, September 10, 2013
Oncolytics Meets Primary Endpoint in U.S. Phase 2 Study of REOLYSIN®
Company has met primary overall statistical endpoint in U.S. Phase 2 clinical trial in SCCLC patients.
Tuesday, May 28, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial
Company announces preliminary results from trial in patients using intravenous administration of REOLYSIN®.
Monday, May 27, 2013
Oncolytics Announces 2012 Year End Results
Company has completed two financings over the last 14 months raising gross proceeds in excess of $50 million.
Tuesday, March 19, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase II Clinical Trial
Investigating REOLYSIN® in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer.
Thursday, February 21, 2013
Oncolytics Announces Additional Positive REOLYSIN® Clinical Trial Data from Phase 2 Study
Study enroll patients with metastatic or recurrent squamous cell carcinoma of the lung.
Monday, February 11, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 SCLC Clinical Trial
Primary objective of the trial is to assess the antitumor effect of the treatment regimen.
Friday, February 01, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase I Clinical Trial
Phase I clinical trial investigate REOLYSIN® in combination with FOLFIRI in patients with colorectal cancer.
Monday, August 27, 2012
Oncolytics Announces Second Quarter 2012 Results
Company announces completion of enrollment in the first, 80-patient stage of Phase III clinical trial in head and neck cancers.
Monday, August 06, 2012
Oncolytics Enters into Sponsorship Agreement with NCIC CTG
Agreement for randomized phase II study in advanced and metastatic breast cancers.
Friday, June 22, 2012
Scientific News
Supplement May Switch off Cravings for High-Calorie Foods
Propionate is made by bacteria in the gut after they digest fiber, with researchers finding higher levels of the substance can curb cravings for junk food.
New CAR T Cell Therapy Using Double Target Aimed at Solid Tumors
Researchers at Penn University have described how antibody, carbohydrate combination could apply to range of cancer types.
Erasing Unpleasant Memories with a Genetic Switch
Researchers from KU Leuven and the Leibniz Institute for Neurobiology have managed to erase unpleasant memories in mice using a 'genetic switch'.
New Method Detects Telomere Length for Research into Cancer, Aging
UT Southwestern Medical Center cell biologists have identified a new method for determining the length of telomeres, the endcaps of chromosomes, which can influence cancer progression and aging.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!